Corporate Member Update: Bristol Myers Squibb
Corporate Member Update: Bristol Myers Squibb
Opdivo
December, 2023
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) as Adjuvant Treatment for Eligible Patients with Completely Resected Stage IIB or Stage IIC Melanoma.
Read the information here.
